(16) proposed to classify SCLC into four subtypes, A, N, Y, and P, based on four transcription factors (ASCL1, NeuroD1, YAP1, and POU2F3), advancing the development of precision therapy for SCLC. This evidence concerns the gene POU2F3 and small cell lung carcinoma.